

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6183395

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	MEDIMMUNE LLC	11/07/2011
RECEIVING PARTY DATA		
Name:	MEDIMMUNE LIMITED	
Street Address:	MILSTEIN BUILDING, GRANTA PARK	
City:	CAMBRIDGE	
State/Country:	UNITED KINGDOM	
Postal Code:	CB21 6GH	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16789790
CORRESPONDENCE DATA		
Fax Number:	(202)371-2540	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(202) 371-2600	
Email:	TTOPSSecretary5@sternekessler.com, smarvin@sternekessler.com	
Correspondent Name:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.	
Address Line 1:	1100 NEW YORK AVENUE, NW	
Address Line 4:	WASHINGTON, D.C. 20005	
ATTORNEY DOCKET NUMBER:	2943.1130004	
NAME OF SUBMITTER:	CYNTHIA L. DERENZO	
SIGNATURE:	/Cynthia L. DeRenzo #60,789/	
DATE SIGNED:	07/02/2020	
Total Attachments: 3		
source=2020-07-01-Company-Assignment-MedImmuneLLC-MedImmuneLimited-2943-1130004#page1.tif		
source=2020-07-01-Company-Assignment-MedImmuneLLC-MedImmuneLimited-2943-1130004#page2.tif		
source=2020-07-01-Company-Assignment-MedImmuneLLC-MedImmuneLimited-2943-1130004#page3.tif		

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 7 day of November 2011 (the "**Effective Date**") by and between

MEDIMMUNE, LLC, a limited liability company formed under the laws of the State of Delaware, whose post office address is One MedImmune Way, Gaithersburg, Maryland 20878, the United States of America ("**Assignor**"); and

MEDIMMUNE LIMITED, a company incorporated in England and Wales whose registered office is Milstein Building, Granta Park, Cambridge CB21 6GH United Kingdom ("**Assignee**").

WHEREAS, Assignor has agreed to assign to Assignee the Assignor's entire right, title and interest in and to the patent applications identified in the attached Schedule (the "**Applications**") and in and to the inventions and improvements disclosed in such Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. In consideration of payments made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely all their legal right, legal title and legal interest in and to the inventions, the Application and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Application and any patents or applications derived therefrom; and the right to file patent applications derived from the Application directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the "**Rights**"), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.




Signed for and on behalf of

MedImmune, LLC

Name: Mita Mukherjee

Title: Authorised Signatory

Date: February 6, 2018



Witnessed by

THE SCHEDULE

APPLICATIONS					
AstraZeneca Case No:	Country	Filing Date	Application No.	Grant No.	Grant Date
PSEUD-101-AU-PCD	Australia	25 Aug 2017	2017219081		
PSEUD-101-BR-PCT	Brazil	07 May 2014	112014011028-0		
PSEUD-101-CA-PCT	Canada	06 May 2014	2,854,817		
PSEUD-101-CN-PCT	China	06 May 2014	201280054651.8	ZL 201280054651.8	18 Aug 2017
PSEUD-101-EP-EPT	EPO	06 Jun 2014	12847479.8		
PSEUD-101-HK-FPR	Hong Kong	27 Feb 2015	15101962.5		
PSEUD-101-ID-PCT	Indonesia	06 Jun 2014	P-00201403334		
PSEUD-101-JP-PCT	Japan	02 May 2014	2014-540196	6182152	28 Jul 2017
PSEUD-101-KR-PCT	South Korea	05 Jun 2014	10-2014-7015274		
PSEUD-101-MO-FPR	Macao	15 Nov 2017	J/002825		
PSEUD-101-MX-PCT	Mexico	07 May 2014	MX/a/2014/005566		
PSEUD-101-NZ-PCD	New Zealand	29 Jul 2016	722379		
PSEUD-101-NZ-PCT	New Zealand	01 Feb 2014	624072	624072	05 Jan 2017
PSEUD-101-RU-PCT	Russia	05 Jun 2014	2014122990		
PSEUD-101-US-PCT	US	06 May 2014	14/356,500		
PSEUD-101-US-PSP	US	07 Nov 2011	61/556,645		
PSEUD-101-US-PSP[2]	US	17 Apr 2012	61/625,299		
PSEUD-101-US-PSP[3]	US	06 Sep 2012	61/697,585		
PSEUD-101-WO-PCT	International Application	06 Nov 2012	PCT/US2012/063722		

PATENT**RECORDED: 07/02/2020****REEL: 053109 FRAME: 0584**